QI
AKCA

QS Investors’s Akcea Therapeutics Inc AKCA Stock Holding History

QS Investors’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-54
Closed -$2K – 1930
2018
Q4 		$2K Hold
54
– – ﹤0.01% 1680
2018
Q3 		$2K Hold
54
– – ﹤0.01% 1684
2018
Q2 		$1K Buy
54
+4
+8% +$95 ﹤0.01% 1910
2018
Q1 		$1K Hold
50
– – ﹤0.01% 1935
2017
Q4 		$1K Buy
+50
New +$980 ﹤0.01% 1942

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

QS Investors's AKCA Position: Q1 2019 in Review

QS Investors sold out of Akcea Therapeutics Inc (AKCA) in Q1 2019, closing a stake of 54 shares — an estimated $2K sold.

QS Investors first reported a position in AKCA in Q4 2017 and held it in 5 quarters. The position peaked at $2K in Q4 2018. 74 funds tracked by Wall St. Rank hold AKCA as of Q1 2019.

  • QS Investors reported no remaining Akcea Therapeutics Inc position as of Q1 2019 after selling out during the quarter.
  • QS Investors sold 54 Akcea Therapeutics Inc shares in Q1 2019, an estimated $2K.
  • QS Investors first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 5 quarters.
  • QS Investors's Akcea Therapeutics Inc position peaked at $2K in Q4 2018.
  • 74 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2019.

Based on QS Investors's 13F filing for Q1 2019, filed 15 May 2019.